FeesSafety
Pluang+

EyePoint faces class action after failed drug trials cause stock to plunge over 85%.

Market News
20 Nov 2026, 23:04 WIB
GlobeNewsWire
View Source
Bearish
EyePoint faces class action after failed drug trials cause stock to plunge over 85%.

EyePoint, Inc. is facing a securities class action lawsuit after its Phase 3 trials for the drug DURAVYU failed to meet primary endpoints, leading to a sharp stock price drop of over 85%. The lawsuit alleges the company made false and misleading statements about the drug's efficacy and prospects. Investors who bought EyePoint stock between May 27, 2025, and August 14, 2026, may seek to recover losses by joining the class action before the January 19, 2027 deadline. This legal action follows the termination of EyePoint's wet AMD program and significant workforce reductions.

EyePoint, Inc. is the subject of a securities class action lawsuit following disappointing Phase 3 trial results. For readers following the health sector, here is Pluang's market snapshot as of Nov 21, 2026 04:02 WIB: out of 150 priced US health stocks, 26 rose and 123 fell. Notable movers include TMDX at USD 85.40 with a 1-day change of -9.17% and 100% buy order activity, SANA at USD 1.58 down 8.91% with 66% sell order activity, and TLRY at USD 1.89 down 8.70% with 93% buy order activity and a typical hold time of 33 days.

More News

Procter & Gamble raises dividend for 70th consecutive year, offering stable income with 2.56% yield.

Procter & Gamble raises dividend for 70th consecutive year, offering stable income with 2.56% yield.

Procter & Gamble has increased its dividend payout for 70 years in a row, demonstrating a strong commitment to rewarding shareholders. The company currently offers a 2.56% dividend yield, which is higher than the S&P 500 average, providing a reliable...

Others
Bullish
1 hour ago
Australian Oilseeds Holdings warned by Nasdaq for not meeting $2.5M equity rule, must submit compliance plan by Jan 2027

Australian Oilseeds Holdings warned by Nasdaq for not meeting $2.5M equity rule, must submit compliance plan by Jan 2027

Australian Oilseeds Holdings Limited received a Nasdaq notification for failing to meet the minimum stockholders' equity requirement of $2.5 million, reporting a deficit of over $4.3 million as of June 30, 2026. The company also does not meet alterna...

Market News
Bearish
1 hour ago
Avalo Therapeutics grants stock options to new hires as inducements under Nasdaq rules.

Avalo Therapeutics grants stock options to new hires as inducements under Nasdaq rules.

Avalo Therapeutics has granted inducement stock options totaling 52,000 shares to three new employees, with an exercise price of $6.70 per share. These options vest over four years, starting one year after employment begins, to incentivize and retain...

Company Fundamentals
Neutral
1 hour ago
J&J Snack Foods plans sales growth in 2027 despite rising distribution costs, aided by cost savings and product expansion.

J&J Snack Foods plans sales growth in 2027 despite rising distribution costs, aided by cost savings and product expansion.

J&J Snack Foods reported a 21.6% rise in distribution costs in Q4 2026 due to higher freight and fuel expenses, pressuring near-term earnings. However, the company achieved $25 million in annualized savings through Project Apollo, improving gross mar...

Company Fundamentals
Bullish
1 hour ago
BJ's sales rise 17.7% with 200K new members; plans 30 new stores by 2028 to boost growth.

BJ's sales rise 17.7% with 200K new members; plans 30 new stores by 2028 to boost growth.

BJ's Wholesale Club reported a 17.7% year-over-year increase in net sales for Q3 2026, driven by over 200,000 new members signed up in October and a 6% rise in store traffic during a promotional event. The company reinvested $240 million from a litig...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App